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EGFR is the best studied receptor tyrosine kinase. Yet, a comprehensive mechanistic understanding of
EGFR signaling is lacking, despite very active research in the field. In this paper, we investigate the role of the
juxtamembrane (JM) domain in EGFR signaling by replacing it with a (GGS)10 unstructured sequence. We
probe the effect of this replacement on (i) EGFR phosphorylation, (ii) EGFR dimerization and (iii) ligand
(EGF) binding. We show that the replacement of EGFR JM domain with a (GGS)10 unstructured linker
completely abolishes the phosphorylation of all tyrosine residues, without measurable effects on receptor
dimerization or ligand binding. Our results suggest that the JM domain does not stabilize the inactive EGFR
dimer in the absence of ligand, and is likely critical only for the last step of EGFR activation, the
ligand-induced transition from the inactive to active dimer.
E
GFR is a receptor tyrosine kinase (RTK) which plays a critical role in cell proliferation, differentiation,
survival and migration1,2. It also plays a complex role in carcinogenesis and cancer progression, and is thus
an attractive candidate for anticancer therapies1,3. While there are significant benefits of anti-EGFR agents
in some solid tumors including colorectal, neck, lung, and pancreatic tumors, many challenges remain in the
improvement of the targeted EGFR therapies4,5. In part, this is due to a lack of comprehensive mechanistic
understanding of EGFR signaling, despite very active research in the field.
EGFR, like all RTKs, consists of a ligand-binding extracellular (EC) domain, a single transmembrane domain
and an intracellular portion composed of a juxtamembrane (JM) sequence, a kinase domain related to soluble
kinases, and a C-terminal tail. EGFR activation is initiated upon EGFR dimerization, which brings the two kinase
domains in close proximity. Ligand binding to the dimer induces a conformational change which propagates into
the intracellular domain, and as a result one of the kinase domains catalyzes the phosphorylation of critical
tyrosine residues on the C-terminal tail of the neighboring receptor6. This is followed by the phosphorylation of
additional intracellular tyrosine residues, which serve as binding sites for docking proteins. Upon recruitment
and/or phosphorylation, these docking proteins initiate intracellular signaling cascades that control growth,
differentiation, and motility7–9.
EGFR has been the most widely and in-depth studied RTK. Thus, we now have extensive knowledge about
many of the specific interactions that are critical for EGFR signal transduction. For instance, it is well known that
EGFR extracellular (EC) domains mediate tight dimer-stabilizing contacts in the presence of bound ligands10,11.
The EGFR dimer is further stabilized by contacts between the two TM domains, which form sequence-specific
dimers in the membrane12,13. The active EGFR kinase dimers are asymmetric, with the C-lobe of one kinase
contacting the N-lobe of the second kinase; these contacts are critical for phosphate transfer and for kinase
activation9.
Recently, evidence has emerged that the JM domain of EGFR, connecting the TM and the catalytic domains, is
important for EGFR dimer stabilization and for EGFR signaling. In particular, the active EGFR dimer has been
proposed to be stabilized by direct contacts between the two JM domains, as well as contacts between the JM
domain and the neighboring kinase14. Furthermore, the deletion of EGFR JM domain has been shown to have
multiple consequences such as altered EGFR dimerization14, aberrant ligand binding15 and decreased phosphor-
ylation16. A mechanistic model of how EGFR JM domain induces these effects and regulated EGFR signaling,
however, is lacking.
In this paper, we revisit the role of the JM domain in EGFR signal transduction, by investigating the con-
sequences of replacing it with a (GGS)10 flexible linker. This experimental design is dictated by a concern that the
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the EGFR dimer. For example, removal of the JM domain may bring
the bulky catalytic domains too close to the intimately interacting a-
helical TM domains. As a result, the observed effects on EGFR activa-
tion will be due to steric hindrance and thus may not give insights
into the role of the JM domain in wild-type EGFR signaling.
Here we probed the effect of the replacement on EGFR activation
and on EGFR dimerization. We further performed ligand titration
experiments to determine if the substitution affects ligand binding.
We show that the replacement of EGFR JM domain with a (GGS)10
linker completely abolishes the phosphorylation of all tyrosine resi-
dues. Unlike experiments in which the JM is deleted, however, the
substitution has no effects on receptor dimerization or on ligand
binding, over the ligand concentration range of 10 to 2500 ng/ml.
Our results demonstrate that the JM domain does not stabilize the
inactive EGFR dimer in the absence of ligand, and is likely critical
only for the last step of EGFR activation, the ligand-induced trans-
ition from the inactive to active dimer.
Results
Replacement of EGFR JM domain by a (GGS)10 flexible linker. To
investigate the role of the JM domains on EGFR function, we
designed a chimeric receptor, EGFR-GGS, in which the JM
domain is replaced by a (GGS)10 sequence (Figure 1). The (GGS)X
sequence has been demonstrated to lack a regular secondary
structure and to be very flexible17. The plasmid was created as
described in Materials and Methods. Briefly, the oligonucleotides
encoding EGFR JM domain (EGFR amino acids 650–680) were
removed by digestion, and annealed oligonucleotides encoding ten
GGS repeats were inserted in their place.
EGFR JM domain is required for EGFR phosphorylation. CHO
cells were transfected with either pcDNA3.1-EGFR or pcDNA3.1-
EGFR-GGS, or the pcDNA 3.1(1) empty vector. 24 hours after
transfection, cells were starved for another day, and then treated
with the growth factor EGF. After lysis, the cell lysates were
subjected to Western blotting. To investigate the effect of JM
domain replacement on EGFR phosphorylation, we used two
different anti-phospho-Tyr antibodies. The first of them, anti-P-
Tyr1068, is specific for phosphorylated tyrosine 1068 in EGFR.
The second one, 4G10, is a non-specific anti-phospho-Tyr
antibody that is reactive to all phospho-tyrosines. In Figure 2A, we
see no anti-P- Tyr1068 and weak 4G10 antibody bands in the absence
of ligand (lane 1: EGFR; lane 3: EGFR-GGS). Upon EGF addition, the
intensities of the anti-P-Tyr1068 and the 4G10 antibody bands are
increased for EGFR (lane 4), indicative of increased phosphorylation.
For EGFR-GGS (lane 6), we see no anti-P-Tyr1068 staining and only
a very weak 4G10 staining band which is also present in the control
cells in the presence of ligand (and thus should not be attributed to
EGF-GGS, lane 5). These results demonstrate that the substitution of
the JM domain with the (GGS)10 linker dramatically reduces EGFR’s
ability for cross-phosphorylation and activation. At the same time,
the substitution does not affect receptor expression. Indeed, the
expression levels of EGFR and EGFR-GGS, as probed by the anti-
EGFR antibodies, are very similar (lanes 1 and 3, and 5 and 6). Thus,
the substitution of the JM domain with an unstructured sequence
abolished EGFR activation.
To ensure that receptor overexpression in the described transient
transfection experiments is not distorting the results; we created cell
lines that stably express the EGFR and EGFR-GGS receptors as
described in Materials and Methods. Briefly, HEK 293 cells were
transfected with the plasmids encoding EGFR and EGFR-GGS.
Twenty four hours after transfection, the cell culture medium was
replaced by selective medium supplemented with GeneticinH. The
medium with antibiotics was replaced every 2–3 days until colonies
of cells could be picked up and screened by immunostaining (data
not shown). The selected colonies were amplified and lysed, and the
lysates were studied using Western blotting. As shown in Figure 2B,
the stable expression results were similar to the results shown in
Figure 2A. EGFR-GGS is not phosphorylated at Tyr 1068, when
assayed using anti-P-Tyr1068 antibodies. None of the other tyrosines
could be phosphorylated either, as demonstrated by 4G10 staining.
Thus, EGFR JM domain is critical for the phosphorylation of all
tyrosines.
The substitution of the JM domain does not affect EGFR cross-
linking. In the literature, dimerization propensities of different
receptors are usually compared using chemical cross-linking18–21.
We therefore compared the cross-linking propensities of EGFR
and EGFR-GGS in CHO cells by incubating the cells with a
membrane-impermeable linker (BS3, Pierce) prior to lysis, as
described in Materials and Methods, followed by Western blotting.
As shown in Figure 3A, both dimers and monomers were observed
on the Western blots. In the absence of ligands, both EGFR and
Figure 1 | Schematics of the plasmids used in the study, encoding wild-
type EGFR and EGFR-GGS. To create the EGFR-GGS plasmid, the
oligonucleotides encoding EGFR JM domain (EGFR amino acids 650–
680) were removed by digestion, and annealed oligonucleotides encoding
ten GGS repeats were inserted in their place as described in Materials and
Methods.
Figure 2 | Activation of EGFR and EGFR-GGS. (A). CHO cells were
transfected with plasmids encoding EGFR (lanes 1 and 4) or EGFR-GGS
(lanes 3 and 6). Lanes 2 and 5 were non-transfected CHO cells. 24 hours
after transfection, cells were starved for another day, and then treated with
EGF (lanes 4, 5, and 6), followed by lysis. Cell lysates were subjected to
Western blotting. (B). HEK 293 cells stably expressing EGFR (lanes 1 and
2), pcDNA 3.1(1) (lane 3) and EGFR-GGS (lanes 4 and 5) were deprived
of serum overnight. The cells were treated with 0 (lanes 1, 3, and 4) and
2500 ng/ml EGF (lanes 2 and 5) for 10 minutes before lysis.
www.nature.com/scientificreports
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EGFR-GGS exhibited dimeric bands (lanes 1 and 3), the intensities of
which increased significantly after the addition of the ligand EGF
(lanes 4 and 6). The cross-linked fraction was calculated as SD/S 5
SD/(SM 1 SD), where SD is the intensity of the dimeric band, and SM is
the intensity of the monomeric band. In the absence of ligand, cross-
linked fractions varied between 0.25 to 0.5. In the presence of ligand,
they varied between 0.45 to 0.9. Figure 3B shows the averages from
three independent crosslinking experiments (0.40 6 0.11 and 0.42 6
0.06 in the absence of ligand and 0.61 6 0.12 and 0.64 6 0.12 in the
presence of ligand). There is no statistical significant difference
between the cross-linked fractions of EGFR and EGFR-GGS (p 5
0.57 and p 5 0.44 in the absence and presence of ligand,
respectively). This result indicates that EGFR cross-linking is not
affected by the replacement of the JM domain with a GGS linker.
The substitution of the JM domain does not affect the FRET
efficiency as a measure of EGFR dimerization in the absence of
ligand. Recently we developed a method that allows us to directly
measure membrane protein dimerization propensities in biological
membranes22,23. Measurements are carried out in plasma membrane
derived vesicles, which bud off cells upon treatments that perturb the
actin cytoskeleton24–26. The detection of dimers is based on FRET and
it thus requires the modification of the receptors with fluorescent
proteins. To pursue this line of inquiry, we created four plasmids en-
coding EGFR-YFP, EGFR-mCherry, EGFR-GGS-YFP, and EGFR-
GGS-mCherry, respectively. Details pertaining to plasmid design
and production are given in Materials and Methods.
CHO cells were cotransfected with either EGFR-YFP and EGFR-
mCherry, or EGFR-GGS-YFP and EGFR-GGS-mCherry. The cells
were then subjected to vesiculation as previously described, and each
plasma membrane-derived vesicle was imaged in a Nikon confocal
microscope22,23,27. About 80 images of vesicles were acquired for each
receptor. However, the expression of these constructs in the plasma
membrane was very low. Thus, as many as 80% of the vesicles
could not be analyzed by the image recognition software because
they were of very low intensity. The highest expression for EGFR
and EGFR-GGS was an order of magnitude lower than the expres-
sion of other membrane proteins that we have studies with this
methodology22,23.
In Figure 4A the measured FRET efficiencies are plotted as a
function of acceptor concentration in the vesicles. Each data point
in Figure 4A corresponds to a single vesicle. Data appear quite scat-
tered, as it can be expected due to the very low receptor concentra-
tion; this scattering is due to white noise associated with image
acquisition22. The solid line corresponds to FRET that is expected
to occur if there are no specific interactions. We see that the
Figure 3 | Cross-linking of EGFR and EGFR-GGS. (A) CHO cells were transfected with plasmids encoding EGFR (lanes 1 and 4) and EGFR-GGS (lanes
2, 3, 5, and 6). 24 hours later, the normal medium was replaced by serum-free medium. After another 24 hours, cells (lanes 4, 5 and 6) were treated with
2500 ng/ml EGF for 10 minutes. Then 2 mM cross-linker BS3 was added to the cells before they were subjected to lysis. Four sets of experiments were
performed, and the results are shown in (B).
Figure 4 | (A) FRET efficiencies measured for EGFR (filled circles) and EGFR-GGS (open circles) in CHO plasma membrane-derived vesicles. Each data
point represents a single vesicle, for which the FRET efficiency and the acceptor concentrations are determined using the QI-FRET method. Also shown is
the FRET efficiency that one expects to see if the receptors do not dimerize (solid line). The measured FRET efficiency is higher than this level for both
receptors. (B) Concentrations of the YFP (donor) and mCherry (acceptor)-tagged receptors in the vesicles analyzed in Figures A.
www.nature.com/scientificreports
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measured FRET is higher than these levels, suggesting that specific
interactions occur for both EGFR and EGFR-GGS.
Since the expression did not vary more than by a factor of three for
all acquired data points, we averaged all the data and compared the
measured FRET efficiencies for EGFR and EGFR-GGS using Student
t-test. The averages 6 standard errors are 0.29 6 0.05 and 0.25 6
0.04. The difference between the FRET efficiencies for the two recep-
tors is not statistically significant (p 5 0.57, based on Student t-test
analysis). Furthermore, there are no significant differences between
the expressions of the two constructs, as shown in Figure 4B.
Binding of EGF to EGFR is not affected by the JM domain
replacement. Next we investigated if the replacement of the JM
domain affects the binding of the ligand EGF to EGFR using flow
cytometry. In the first series of ligand-binding experiments, the EGF
concentration was fixed at 2500 ng/ml. CHO cells were transfected
with plasmids encoding EGFR/WT and EGFR-GGS, as well as an
empty pcDNA 3.1 vector as control. 24 hours after transfection, the
cells were starved for another day, and treated with EDTA to detach
them from the substrate. The suspended cells were split into two cell
pools. The first cell pool was incubated with Alexa Fluor 488-labeled
anti-N-EGFR antibodies, in order to quantify the expression of the
receptors. As this antibody recognized the extracellular domain of
EGFR, it is reactive to both wild-type EGFR and to EGFR-GGS. The
second cell pool was incubated with 2500 ng/ml Alexa Fluor 488-
labeled EGF, to quantify the amount of bound EGF. After incubation
on ice for half an hour and three washes, each cell pool was analyzed
via flow cytometry as described in Materials and Methods. The
expression of the two receptors (as reported by the fluorescence
intensity of the anti-N-EGFR antibodies) and the amount of
bound EGF (as reported by the fluorescence intensity of the bound
EGF) are shown Figure 5A and 5B, respectively. The fluorescence
histogram means were calculated using the FCS Express software (De
Novo Software), and corrected for background. To quantify ligand
binding, the average bound EGF fluorescence values were divided by
the respective average anti-EGFR fluorescence values. The results,
shown in Figure 5C, demonstrate that there is no difference between
EGF-EGFR and EGF-EGFR-GGS binding (p 5 0.58).
To validate these findings, and to explore a wider range of ligand
concentrations, in the second series of ligand-binding experiments
we worked with stable HEK 293 cells. In particular, we used two HEK
293 cell lines that express EGFR and EGFR-GGS at very similar levels
(Figure 6A). Control HEK 293 cells, transfected with empty pcDNA
3.1 vectors, were also incubated with antibodies and ligand and ana-
lyzed at each ligand concentration. The ligand concentrations used
ranged from 10 to 2500 ng/ml, as binding in this ligand concentra-
tion range was measurable in the FACS experiments. As shown in
Figure 6B and 6C, the EGF staining intensities of cells expressing
EGFR and EGFR-GGS increase as the concentration of ligand
increases, indicative of increased binding. The quantitative results
are shown in Figure 6D. To compare the binding of EGF to EGFR
and to EGFR-GGS, we divided the amount of EGFR-GGS-bound
ligand by the amount of EGFR-bound ligand. As shown in
Figure 6E, the ratio is 1 for all tested ligand concentrations (p .
0.05). These experiments demonstrate that the binding of EGF to
EGFR is not affected by the replacement of JM domain by a (GGS)10
linker, over the studied range of ligand concentrations.
Discussion
The intracellular JM domains of several RTKs have been shown to
play autoinhibitory roles by blocking the substrate entry into the
nucleotide-binding pocket28–32. EGFR JM domain, on the other hand,
has been suggested to play a distinctly different, activating role. Thiel
et al. deleted the whole JM domain from the ErbB1 intracellular
domain and observed a severe loss of intracellular domain tyrosine
Figure 5 | Binding of EGF to EGFR and EGFR-GGS, expressed transiently in CHO cells. CHO cells were transfected with plasmids encoding EGFR,
EGFR-GGS and pcDNA 3.11 (control). 24 hours later, the normal medium was replaced by serum-free medium. After another 24 hours, cells were
stained by Alexa Fluo-488 conjugated anti-EGFR antibodies (3A) and Alexa Fluo-488 conjugated EGF (2500 ng/ml) (3B). To quantify the binding of the
receptors to EGF, the geometric means of the fluorescence intensities were calculated using the FCS software. The binding strengths of the ligand to the
two receptors were calculated by dividing the binding intensities by the expression intensities, as shown in 3C. Three independent sets of experiments were
performed.
www.nature.com/scientificreports
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phosphorylation16. Brewer et al. used alanine scanning mutagenesis
and demonstrated that mutations in the C-terminal 19 residues of
the EGFR JM region (664–682) abolished EGFR activation33. In this
work, we designed a chimeric receptor in which the JM domain of
EGFR is replaced by a 30-amino acid long (GGS)10 linker, such that
the chimeric receptor is very similar and of the same length as wild
type EGFR. This substitution is not expected to affect the TM and
kinase domains because GGS-linkers have been shown to decouple
the proteins that they are linked to, and not to perturb their structure
and function17. This construct allowed us to study the effect of the JM
domain on EGFR activation without introducing structural con-
straints within the EGFR dimers. After the replacement, we observed
a complete abolishment of EGFR phosphorylation at all tyrosine sites
(Figure 2). This result is consistent with published results and
highlights the critical role that EGFR JM domain plays in EGFR
activation.
Here we also investigated the role of the JM domain in ligand-
independent EGFR dimerization. We performed both cross-linking
and FRET experiments in the absence of ligand. We observed cross-
linked bands in the Western blots for both EGFR and EGFR-GGS.
We also observed high FRET efficiencies for the two receptors. These
results suggest that both receptors form dimers in the absence of
ligand. As shown in Figure 3B, about 40% of the receptors are
cross-linked. Yet, we see no EGFR-GGS activity in all cases, no
EGFR activity in the stable cell lines, and very weak EGFR activity
in the transient transfection experiments. Thus, all EGFR-GGS
and the majority of EGFR molecules are inactive in the absence of
ligand.
Figure 6 | Binding of EGF to EGFR and EGFR-GGS, expressed stably in HEK cells. (A) Flow cytometry data for HEK 293 cells stably expressing EGFR,
EGFR-GGS and empty pcDNA 3.1 (1) vectors. Cells were stained with Alexa Fluo-488 conjugated anti-EGFR antibodies or Alexa Fluo-488 conjugated
EGF at concentrations of 10, 100, 1000 and 2500 ng/ml. (B) Binding of EGF, at different concentrations, to EGFR. (C) Binding of EGF, at different
concentrations, to EGFR-GGS. (D) The geometric means of the fluorescence intensities of bound antibodies and bound ligands were calculated using the
FCS software. EGF binding was normalized by the receptor expression levels. (E) Ratios of EGFR-bound EGF to EGFR-GGS bound EGF, as a function of
EGF concentrations.
www.nature.com/scientificreports
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While details about the inactive dimer are unknown, Jura et al
crystallized a symmetric kinase dimer, presumably in the inactive
conformation14. Contacts between the two kinase domains in this
inactive dimer are mediated by parts of the C-terminal tail. In par-
ticular, residues 967 to 978 form a helix which packs against the
neighboring kinase, while residues 979–981 salt-bridge with residues
on the neighboring kinase. Additional insight about the structure of
the EGFR unliganded dimer comes from experiments performed by
Linda Pike and colleagues, who used luciferase complementation
imaging to follow conformational changes in the receptor upon
ligand stimulation34. The two fragments of the luciferase comple-
mentation system, NLuc and CLuc were fused to the C-terminus
of EGFR. These fragments are not capable of producing light by
themselves as monomers but are capable of forming an active luci-
ferase if brought into close proximity. The researchers observed sig-
nificant luciferase activity in the absence of ligand, which suggested
that the unliganded EGFR dimer adopted a conformation in which
the C-terminal tails of the two monomers were in close proximity of
each other, such that the two fragments can form a functional
enzyme34. This is generally consistent with Jura’s crystal structure
of the inactive dimer14. Since the C-terminal tail packs at the interface
between the two kinases, it is likely that the two terminal ends to
which NLuc and CLuk are attached are also in close proximity such
that a functional luciferase can be formed34.
The attachment of the fluorescent proteins in our FRET experi-
ments was the same as in Pike’s experiments, and therefore the
fluorescent proteins in the dimer are expected to be in close prox-
imity of each other. The dimeric fractions (f) can be obtained from





In this equation ED is the measured FRET efficiency (symbols in
Figure 4A), corrected for the FRET due to random proximity of
donors and acceptors (solid line in Figure 4A). XA is the acceptor
fraction (concentration of acceptors over concentration of donors
and acceptors), which is known, i.e. determined with the QI-FRET
method. The parameter ~E is the FRET efficiency of a dimer with both
a donor and an acceptor present. The value of ~E is dependent upon
the separation distance between the donor and the acceptor in the
dimer, i.e. on the structure of the dimer. As the experiments of Pike
and colleagues suggest that the fluorescent proteins are in close prox-
imity, we can estimate the distance between them and therefore we
can estimate ~E34. As the size of the fluorescent proteins is about 40 Å,
the closest possible distance between the two fluorophores is 40 Å.
Since the Foster radius is 53 Å, ~E can be calculated as 84%, and the
dimeric fraction for EGFR should be about 40%. Even if we assume
that the distance between the two fluorophores is 50 Å, the dimeric
fraction of EGFR would be about 55%. These back-of-the-envelope
calculations suggest that about 40 to 50% of the receptors pre-dimer-
ize in the absence of ligand, consistent with the cross-linking results
in Figure 3. As the FRET efficiencies recorded for EGFR and EGFR-
GGS are the same (Figure 4), and the crosslinked fractions are the
same (Figure 3), it is likely that ~E is the same for both receptors. We
can thus speculate that the structures of the kinase dimers in the
unliganded EGFR and EGFR-GGS dimers are the same, and likely
the same as the symmetric inactive structure proposed by Jura and
colleagues14. As we do not expect any stabilizing contacts between the
(GGS)10 unstructured sequences in EGFR-GGS, we deduce that there
are no direct JM-JM domain stabilizing contacts in the inactive EGFR
dimer.
Next we asked whether the abolished phosphorylation at high
ligand concentration is at least in part due to aberrations in ligand
binding. This was a possibility, since experiments by Macdonald-
Obermann and Pike have suggested that the JM domain affects
ligand binding to EGFR via an intricate allosteric mechanism15. To
investigate if binding is affected by the substitution of EGFR JM
domain with the (GGS)10 flexible linker, we first assayed ligand
binding in transient transfection experiments at high ligand concen-
tration. We saw no differences in the ligand binding affinities of
EGFR and EGFR-GGS (Figure 5). This result suggests that the loss
of intracellular tyrosine kinase activity at saturating ligand concen-
tration that we observe after the replacement of the JM domain
with the (GGS)10 linker does not occur because of impaired ligand
binding.
To further our confidence in this conclusion, we created HEK 293
stable lines that exhibit the same EGFR and EGFR-GGS expression,
and we studied ligand binding over the ligand concentration range
from 10 ng/ml to 2500 ng/ml. Again, we saw no differences in the
ligand binding affinities of EGFR and EGFR-GGS (Figures 6) over
the ligand concentration range that was accessible in the FACS
experiments.
The results presented here can give insight into the role of the JM
domain in EGFR activation models. There are models of EGFR
activation in the literature which describe some experimental data
very well, such as the ‘‘model of EGF binding in an aggregating
system’’ proposed by Linda Pike and colleagues36. In this model
EGFR monomers and dimers coexist in the absence of ligand, and
ligand can bind to monomers, to unoccupied dimers, or to dimers
bound to one ligand. However, the activation of EGFR is a very
complex process, and even this model is likely an oversimplification,
since it does not account explicitly for EGFR activation in the
liganded state, i.e. for the transition from an inactive to an active
dimer upon ligand binding.
In our experiments we see a substantial population of inactive
dimers in the absence of ligand, consistent with previous reports37–40.
Therefore, we can assume that a large fraction of EGFR molecules
likely gets activated in a three-step process consisting of: (1) EGFR
dimerization in the absence of ligand, yielding an inactive dimer, (2)
ligand binding to this dimer, followed by a (3) transition to an active
dimer. It is already known that the final active state cannot be
attained without the JM domain. Here we demonstrate that the JM
domain does not stabilize the inactive EGFR dimer. We also dem-
onstrate that JM domain does not affect ligand binding at high ligand
concentration. Our results therefore suggest that the major role of
the JM domain is in the last step of EGFR activation, the transition
from the inactive to an active dimer.
Methods
Plasmid constructs. The pcDNA3.1-EGFR plasmid was a generous gift from
Professor Daniel Leahy, Johns Hopkins University. To replace the 30 amino acid-long
JM domain by 10 GGS repeats, we created two restriction enzyme sites in the
pcDNA3.1-EGFR plasmid using a multisite mutagenesis kit (Stratagene). In
particular, a HindIII site was introduced before the JM domain and an EcoRI site was
introduced after the JM domain. The plasmid was then double digested. DNA
oligomers encoding ten GGS repeats were synthesized by Invitrogen and ligated to the
digested pcDNA3.1-EGFR vector to create pcDNA3.1-EGFR-GGS. The successful
substitution of EGFR JM domain with a (GGS)10 linker was confirmed by sequencing
provided by Genewiz (Germantown, MD). To tag the receptors with fluorescent
proteins at the C-terminus, the genes encoding EGFR and EGFR-GGS were amplified
using PCR and the stop codons were removed. The PCR products were ligated
between the NheI and KpnI sites in the pcDNA 3.1 (1) vector. The genes encoding
the fluorescent proteins were amplified by PCR and two restriction enzyme sites were
created: a KpnI site before the fluorescent protein DNA, and an XbaI site was after the
stop codon. The amplified genes were inserted between the KpnI and the XbaI sites in
pcDNA 3.1-EGFR and pcDNA 3.1-EGFR-GGS.
Cell culture. CHO cells were cultured in Dulbecco’s modified Eagle’s medium
(Invitrogen, CA) supplemented with 10% fetal bovine serum (Thermo Scientific) and
nonessential amino acids (Gibco, CA). Human embryonic kidney (HEK) 293 cells
were cultured in DMEM supplemented with 10% fetal bovine serum (FBS). All cells
were maintained in the incubator with 5% CO2 at 37uC.
Creation of stable cell lines. HEK 293 cells were transfected with pcDNA3.1-EGFR-
GGS, pcDNA3.1-EGFR, or pcDNA 3.1(1) empty vectors using Fugene HD (Roche
Applied Science) following the manufacturer’s protocol. Twenty four hours after
www.nature.com/scientificreports
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transfection, the culture medium was replaced by medium supplemented with 0.6 mg/
ml GeneticinH (G418, Invitrogen). Two or 3 days later, the cells that grew to about
90% confluency were passed and seeded with high dilution ratio into 150-mm cell
culture dishes. The medium with antibiotics was replaced every 2–3 days until
colonies of cells appeared around 2 weeks after the initial seeding. 12 colonies from
each dish were selected and cultured in 24-well plates. The expression levels of EGFR
and EGFR-GGS were estimated by immunostaining, and further assayed by Western
blots and Flow Cytometry.
Western blots. CHO cells were transfected with either pcDNA3.1-EGFR-GGS or
pcDNA3.1-EGFR, or pcDNA 3.1(1) empty vectors. These cells, as well as the HEK
293 stable cell lines, were starved in serum-free DMEM for 24 hours. The cells were
treated with lysis buffer [25 mM Tris–HCl, 0.5% Triton X-100, 20 mM NaCl, 2 mM
ethylenediaminetetraacetic acid, 2 mM NaVO4 and protease inhibitor (Roche
Applied Science)]. After centrifugation at 15,000 g for 15 min at 4uC, the supernatant
was collected, and the pellet was discarded. Protein concentration was determined
using the BCATM assay kit (Pierce, IL). The lysates were loaded into 3–8% NuPAGEH
NovexH Tris–acetate mini gels (Invitrogen). Proteins were separated by
electrophoresis and transferred onto a nitrocellulose membrane. The membrane was
blocked with milk for 1 h at room temperature and then stained with anti-N-EGFR
antibodies (Cell Signaling Technology), anti-P-Tyr1068 antibodies (Cell Signaling
Technology), anti-phospho-Tyr, clone 4G10H antibodies (Millipore), The secondary
antibodies were either anti-rabbit or anti-mouse horseradish-peroxidase-conjugated
antibodies (Promega, WI). ECLTM detection reagent (GE Healthcare Life Sciences,
UK) was used to visualize the Western blot bands. The bands were quantified using
ImageQuant TL (GE Healthcare Life Sciences).
The Western blot films were scanned and processed with ImageQuant TL. At least
three sets of independent experiments were performed to determine the averages and
the standard deviations as described41–45.
Flow cytometry measurements. Cells were starved in serum-free DMEM for 24 hours
and then suspended in 5 mM EDTA and washed with 3% FBS/PBS. EGFR and EGFR-
GGS expressed on the cell surface were detected with anti-N-EGFR antibodies
conjugated with Alexa Fluoro 488 (Santa Cruz biotechnology). The binding of EGF to
the receptors was measured using Alexa Fluoro 488 conjugated EGF (Invitrogen).
Measurements were performed with a FACSCalibur flow cytometer (BD Biosciences).
The expression levels of EGFR and EGFR-GGS, and the binding of EGF to the
receptors was determined using the FCS express software (De Novo Software).
Cross-linking. In cross-linking experiments, dimeric EGFR or EGFR-GGS receptors
were cross-linked with a membrane-impermeable cross-linker BS3
(bis(sulfosuccinimidyl) suberate, Pierce). Twenty four hours after transfection, cells
were incubated with 2 mM cross-linker for 30 min at room temperature and then
quenched in 20 mM Tris-HCl for 15 min. After a rinse with ice-cold PBS, the cells
were lysed, and the receptors were detected using Western blotting. The cross-linked
fraction was calculated as SD/S 5 SD/(SM 1 SD), where SD is the intensity of the
dimeric band, and SM is the intensity of the monomeric band.
Vesiculation. CHO cells were seeded in a 6-well plate at a density of 63104 cells/well
one day prior to transfection. Cells were transfected using Fugene HD (Roche Applied
Science) following the manufacturer’s protocol. Cells were co-transfected with
pcDNA_EGFR_YFP and pcDNA_EGFR_mCherry or pcDNA_EGFR-GGS-YFP and
pcDNA_EGFR-GGS-mCherry. Vesiculation was performed using a previously
described method24–26. Briefly, cells were rinsed twice with PBS (pH 7.4) containing
0.75 mM calcium and 0.5 mM magnesium (CM-PBS), and once with vesiculation
buffer consisting of CM-PBS with 25 mM formaldehyde and 0.5 mM 1,4-dithiotreitol
(DTT). The cells were then incubated at 37uC with 1 mL of vesiculation buffer for
2 hours. To quench the formaldehyde in the vesiculation buffer, glycine solution was
added to a final concentration of 0.125 M. These vesicles have been shown to be an
adequate model of the plasma membrane46. The vesicles were transferred into an 8-
well Nunc Lab-Tek II chamber slide and allowed to settle for 1 hour before imaging.
FRET experiments. Images of vesicles were acquired using a Nikon Eclipse confocal
laser scanning microscope with a 60X water immersion objective. All the images were
collected and stored at a 5123512 resolution. Three different scans were performed
for each vesicle: (1) excitation at 488 nm, with a 500–530 nm emission filter (donor
scan); (2) excitation at 488 nm, with a 565–615 nm emission filter (FRET scan); and
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were used for all the three scans. To minimize the bleaching of fluorescent proteins,
ND8 filters were used during excitation with the 488 nm laser, and pixel dwell time
was set to the minimum (1.68 ms). These images were analyzed with a Matlab program
developed in the lab, which automatically recognizes the vesicles and calculates the
intensities in the three channels as previously described22,23.
Statistical analysis. All experiments were repeated at least three times to determine
the averages and the standard deviations. Student t-test was used to compare the
measurements to a null hypothesis for statistical significance, as previously
described43,44. The p-value cutoff for significance is 0.05.
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